Scholarlink

Background <p>Cancer patients will have an increased incidence of corona virus disease 2019 (COVID-19) infection. The severity of COVID-19 infection varies among cancer patients who have other complications and are being treated.</p> Method <p>This retrospective cohort study evaluated the impact of cancer treatments on COVID-19 incidence and outcomes in 603 cancer patients. Key objectives included assessing treatment-related risks, severity, and treatment efficacy, along with the effects of treatment interruptions on patient recovery and therapy resumption.</p> Result <p>This study included 603 cancer patients, of whom 68 (11.28%) were infected with COVID-19, and 398 (66%) were vaccinated. Logistic regression analysis revealed that underlying comorbidities, chemotherapy, and radiotherapy were significantly associated with an increased risk of COVID-19 infection (<i>P</i> &lt; 0.05 for chemotherapy and radiotherapy). Factors such as sex, smoking status, cancer pathology, and staging showed no significant correlation with COVID-19 incidence. Treatment disruptions during the pandemic were observed, with chemotherapy being most affected (42.86% suspension), while surgery and TKI therapy showed minimal interruption. Efficacy analysis indicated no significant difference in treatment outcomes between suspended and uninterrupted treatments (<i>P</i> = 0.758). Treatment suspensions did not significantly alter toxicity profiles, with bone marrow suppression being the most frequent toxicity.</p> Conclusion <p>Chemotherapy and radiotherapy increased the risk of COVID-19 in cancer patients, with treatment interruptions not affecting efficacy or toxicity, underscoring the need for tailored management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating the impact of COVID-19 on cancer care: a comprehensive analysis of treatment modifications, risk factors, and patient outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月2日

查看全文
  • Xuquan Jing,
  • Min Wang,
  • Shuangqing Lu,
  • Jiling Niu,
  • Feihu Chen,
  • Hanjing Yin,
  • Haoyu Liu,
  • Dongmei Sun,
  • Hui Zhu

摘要

Background

Cancer patients will have an increased incidence of corona virus disease 2019 (COVID-19) infection. The severity of COVID-19 infection varies among cancer patients who have other complications and are being treated.

Method

This retrospective cohort study evaluated the impact of cancer treatments on COVID-19 incidence and outcomes in 603 cancer patients. Key objectives included assessing treatment-related risks, severity, and treatment efficacy, along with the effects of treatment interruptions on patient recovery and therapy resumption.

Result

This study included 603 cancer patients, of whom 68 (11.28%) were infected with COVID-19, and 398 (66%) were vaccinated. Logistic regression analysis revealed that underlying comorbidities, chemotherapy, and radiotherapy were significantly associated with an increased risk of COVID-19 infection (P < 0.05 for chemotherapy and radiotherapy). Factors such as sex, smoking status, cancer pathology, and staging showed no significant correlation with COVID-19 incidence. Treatment disruptions during the pandemic were observed, with chemotherapy being most affected (42.86% suspension), while surgery and TKI therapy showed minimal interruption. Efficacy analysis indicated no significant difference in treatment outcomes between suspended and uninterrupted treatments (P = 0.758). Treatment suspensions did not significantly alter toxicity profiles, with bone marrow suppression being the most frequent toxicity.

Conclusion

Chemotherapy and radiotherapy increased the risk of COVID-19 in cancer patients, with treatment interruptions not affecting efficacy or toxicity, underscoring the need for tailored management.